Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing treatment options for neurodegenerative diseases and endocrine conditions. Its lead investigational product is Avexitide, a first-in-class GLP-1 receptor antagonist currently in phase 3 clinical trials for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, which is in phase 2 trials for Wolfram syndrome and phase 2b/3 trials for progressive supranuclear palsy. Additionally, Amylyx is advancing AMX0114 for amyotrophic lateral sclerosis (ALS) in phase 1 trials and AMX0318, another GLP-1 receptor antagonist for post-bariatric hypoglycemia and rare diseases. The company operates solely in the United States.

Amylyx Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AMLX. Its shares are traded in U.S. dollars (USD), as the company is headquartered in the United States and its primary listing is on a U.S. exchange.

Amylyx Pharmaceuticals operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development and manufacturing of pharmaceutical drugs, with a focus on specialty treatments for specific diseases rather than broad-market medications. As a clinical-stage company, it has not yet brought any products to market, but its pipeline targets neurodegenerative and endocrine conditions.

Amylyx Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States. The company serves the U.S. market, as indicated by its description summary, which states it provides discovery and development of treatment options in the United States. Its clinical trials are conducted in the U.S., and its regulatory filings target the U.S. Food and Drug Administration (FDA).

Amylyx Pharmaceuticals' pipeline includes several investigational therapies. Avexitide is a first-in-class GLP-1 receptor antagonist in phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. AMX0035, an oral combination of sodium phenylbutyrate and taurursodiol, is being studied in phase 2 for Wolfram syndrome and phase 2b/3 for progressive supranuclear palsy. AMX0114 targets amyotrophic lateral sclerosis (ALS) in phase 1 trials. Additionally, AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and rare diseases. All products are in clinical development and not yet approved for commercial use.